Table 1.
Clinicopathological characteristics of enrolled patients.
| Training set |
Validation set |
|||||
|---|---|---|---|---|---|---|
| Malignant (n = 197) | Benign (n = 63) | P value | Malignant (n = 93) | Benign (n = 29) | P value | |
| Age, median (range), y | 60 (21–81) | 57 (21–72) | 002 | 57 (27–79) | 54 (26–76) | 71 |
| Sex | 03 | 67 | ||||
| Male | 80 (41) | 36 (57) | 40 (43) | 14 (48) | ||
| Female | 117 (59) | 27 (43) | 53 (57) | 15 (52) | ||
| MTD, mean (SD), cm | 1·52 (0·709) | 1·40 (0·656) | 35 | 1·51 (0·74) | 1·51 (0·76) | 98 |
| Serum biomarkers, mean (SD)a | ||||||
| CEA, ng/mL | 2·75 (5·33) | 1.25 (0·53) | 01 | 2.72 (5·47) | 1.44 (0·59) | 37 |
| CYFRA21-1, ng/mL | 2·00 (1·36) | 1·26 (0·75) | <001 | 1·89 (1·38) | 1·53 (0·73) | 67 |
| NSE, ng/mL | 13·93 (7·13) | 11·07 (5·04) | 007 | 12·50 (4·12) | 11·45 (5·63) | 17 |
| SCC, ng/mL | 1·01 (0·76) | 0·89 (0·33) | 26 | 1·07 (0·91) | 1·13 (1·01) | 92 |
| Pathological subtype | ||||||
| Adenocarcinoma | 171 (87) | 85 (91) | ||||
| Squamous cell carcinoma | 10 (5) | 3 (3) | ||||
| Small cell lung cancer | 3 (2) | 0 | ||||
| Others | 13 (7) | 5 (5) | ||||
| Clinical stage | ||||||
| 0 (Tis) | 30 (15) | 21 (23) | ||||
| I | 149 (76) | 66 (71) | ||||
| II | 5 (3) | 3 (3) | ||||
| III | 6 (3) | 2 (2) | ||||
| Uncertain | 7 (4) | 1 (1) | ||||
a
In the training set, 117 lung cancer patients and 37 benign lung disease patients were randomly selected to receive serum biomarker tests. In the validation set, 52 lung cancer patients and 16 benign lung disease patients were randomly selected to receive serum biomarker tests.